楚天科技(300358.SZ):擬將“醫藥裝備與材料技術研究中心項目”延期至2026年3月
格隆匯2月28日丨楚天科技(300358.SZ)公佈,公司於2025年2月28日召開第五屆董事會第三十三次會議、第五屆監事會第二十四次會議,審議通過了《關於部分募集資金投資項目延期的議案》。公司在保持募集資金投資項目的實施主體、投資總額和資金用途等不發生變化的情況下,結合當前行業形勢,審慎考慮放緩對“醫藥裝備與材料技術研究中心項目”的建設進度。根據募集資金投資項目當前的實際建設進度,同意將“醫藥裝備與材料技術研究中心項目”達到預定可使用狀態的時間延長至2026年3月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.